Novavax
NVAX Small CapHealthcare · Biotechnology
Aggiornato: May 2, 2026, 22:05 UTC
Metriche Chiave
Analisi della Valutazione
Informazioni sull'Azienda
Novavax Stock at a Glance
Novavax (NVAX) is currently trading at 6,86 € with a market capitalization of 1,1 Mrd. €. The trailing P/E ratio stands at 3.12x. The 52-week range spans from 4,95 € to 10,21 €; the current price is 32.8% below the yearly high. Year-over-year revenue growth stands at +66.6%. The net profit margin stands at 39.19%.
💰 Dividendo
Novavax currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Raccomandazioni degli Analisti
9 analysts rate Novavax (NVAX) on consensus: Comprare. The average price target is 11,94 €, implying +74.16% from the current price. Analyst price targets range from 5,97 € to 21,33 €.
Tesi di Investimento: Punti di Forza e Debolezze
- Strong revenue growth of 66.6% YoY
- Profitable with 39.19% net margin
- High gross margin of 63.52% — indicates pricing power
- Analyst consensus: Buy
- Currently flagged as undervalued
- –High volatility (Beta 2.65)
- –High short interest (28.54%)
- –Negative free cash flow
Panoramica Tecnica
The price is in a transition zone relative to the moving averages — no clear signal.
Profilo di Rischio
The data points to above-average price swings, elevated short interest (28.54%).
Dati di Trading
Azioni Correlate nello Stesso Settore
Where can I buy Novavax?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
